An impressive array of Big Pharma backers have lined up to ensure Strand Therapeutics has the funding needed to take its mRNA ...

Lilly paid $47.5 million upfront to license the non-opioid pain drug candidate CNTX-0290 from Centrexion in 2019. The SSTR4 ...

Minghui Pharmaceutical has secured $131 million in what the company describes as a “pre-IPO” round to fuel the potential ...

As other pharmas drop next-gen obesity assets, Eli Lilly’s experimental oral GLP-1 has prompted weight loss up to an average ...

Keros Therapeutics has shaken up its leadership structure as the bi | Keros has shaken up its leadership structure as the ...

Gilead has returned the rights to a cancer candidate it licensed from Arcus Biosciences in a $725 million, multiprogram deal, ...

Ryght AI traveled down country roads to find the newest member of its growing clinical trial site collection. | Ryght AI ...

Heartflow has pumped up its IPO ambitions, raising its proposal into the vicinity of $300 million. | After first pricing its ...

Astria took the candidate, a monoclonal antibody inhibitor of plasma kallikrein called navenibart, into a late-stage study off the back of a phase 1b/2 trial last year that tied the drug to up to a 92 ...

Alltrna, the preclinical Flagship Pioneering-backed biotech trying to turn transfer RNA (tRNA) into drugs, is slimming down as it works toward the clinic.  | Alltrna, the preclinical Flagship ...

The Trump administration has broken the law by withholding funds that Congress had allocated to the National Institutes of Health (NIH), according to the Government Accountability Office (GAO).